This is, to our knowledge, the first study to report a predictive tumor-cell-associated protein biomarker for CNS relapse in early-stage NSCLC and the first study to report the correlation between NRF2 expression in CK+ cells and the risk of CNS relapse. Here, NFE2L2 is linked to neoplasm.